Targeting of KRAS mutant tumors by HSP90 inhibitors involves degradation of STK33

Previous efforts to develop drugs that directly inhibit the activity of mutant KRAS, the most commonly mutated human oncogene, have not been successful. Cancer cells driven by mutant KRAS require expression of the serine/threonine kinase STK33 for their viability and proliferation, identifying STK33...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Azoitei, Ninel, Hoffmann, Christopher M., Ellegast, Jana M., Ball, Claudia R., Obermayer, Kerstin, Gößele, Ulrike, Koch, Britta, Faber, Katrin, Genze, Felicitas, Schrader, Mark, Kestler, Hans A., Döhner, Hartmut, Chiosis, Gabriela, Glimm, Hanno, Fröhling, Stefan, Scholl, Claudia
Format: Artigo
Idioma:Inglês
Publicat: The Rockefeller University Press 2012
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3328372/
https://ncbi.nlm.nih.gov/pubmed/22451720
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1084/jem.20111910
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars